A compound chimeric antigen receptor strategy for targeting multiple myeloma

Current clinical outcomes using chimeric-antigen receptors (CARs) against multiple myeloma show promise in the eradication of bulk disease. However, these anti-BCMA (CD269) CARs observe relapse as a common phenomenon after treatment due to the reemergence of either antigen-positive or -negative cell...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, K H, Wada, M, Pinz, K G, Liu, H, Shuai, X, Chen, X, Yan, L E, Petrov, J C, Salman, H, Senzel, L, Leung, E L H, Jiang, X, Ma, Y
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2018
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5808076/
https://www.ncbi.nlm.nih.gov/pubmed/28951562
http://dx.doi.org/10.1038/leu.2017.302

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5808076/
https://www.ncbi.nlm.nih.gov/pubmed/28951562
http://dx.doi.org/10.1038/leu.2017.302

Ejemplares similares